Kidney transpantation Surgery Kidney transpantation
Conditions
Interventions
Patients who fulfill the selection criteria and are willing to participate will be asked to complete a consent form, after reading a participant information leaflet. Treatment allocation is performed
Sponsors
The Polish Ministry of Science and Higher Education
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Kidney transplant candidate on active waiting list assigned to transplantation in Wroclaw Medical University Hospital 2. Aged 18 years and over 3. Provision of written informed consent
Exclusion criteria
Exclusion criteria: 1. Decline participation in this study 2. Unable to comply with requirements of this study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Graft function is determined by measuring eGFR (using MDRD formula) at 7 days, 14 days, 1, 3, 6, 12, 18, 24 and 60 months post-transplantation 2. Graft survival is measured through medical record review and patient urine output 7 days, 14 days, 1, 3, 6, 12, 18, 24 and 60 months post-transplantation 3. Delayed graft function rate is assessed through reviewing patient notes for dependence on haemodialysis at 7 days, 14 days, 1, 3, 6, 12, 18, 24 and 60 months post-transplantation 4. Rejection episode rate is determined through medical note review at 7 days, 14 days, 1, 3, 6, 12, 18, 24 and 60 months post-transplantation | — |
Secondary
| Measure | Time frame |
|---|---|
| Relationship between intragraft gene expression (B1,B2,B3) and post-transplant clinical parameters (patient and graft survival, graft function described as eGFR, delayed graft function and acute rejection episodes) are assessed at 7 days, 14 days, 1, 3, 6, 12, 18, 24 and 60 months post-transplantation | — |
Countries
Poland
Outcome results
None listed